<DOC>
	<DOCNO>NCT03059849</DOCNO>
	<brief_summary>To examine whether temporary three month increase adalimumab dose prevent relapse patient inflammatory bowel disease clinical remission elevate calprotectin .</brief_summary>
	<brief_title>Brief Escalation Adalimumab Treatment Prevention Clinical Relapse IBD</brief_title>
	<detailed_description>Patients use adalimumab Crohn 's disease ulcerative colitis clinical remission follow fecal calprotectin monitoring every 3 month . Patients sustain rise calprotectin maintain clinical remission offer opportunity increase adalimumab three month . Patients use three month increase adalimumab dose compare patient use increased dosing determine relapse rate differ two group .</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Adults age 18 old Crohn 's disease ulcerative colitis 2 . Patients clinical remission accord last 'Abbvie Care ' clinical symptom assessment ( use Partial Mayo score &lt; 2 HarveyBradshaw Index &lt; 4 ) 3 . Patient use adalimumab dose least 40mg subcutaneously biweekly , maximum dose 40mg subcutaneously weekly ( 80mg subcutaneously biweekly ) . 1 . Pregnant woman plan pregnancy within 3 month study inclusion 2 . Abdominal abscess 3 . Inability unwillingness provide inform consent 4 . Any condition , , opinion investigator would impede competence compliance possibly hinder completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>